First-in-human, randomized, double-blind, placebo-controlled, dose escalation trial of the anti-herpes simplex virus monoclonal antibody HDIT101 in healthy volunteers.
Blank A, Hohmann N, Dettmer M, Manka-Stuhlik A, Mikus G, Stoll F, Stützle-Schnetz M, Thomas D, Exner E, Schmitt-Bormann B, Schaller T, Laage R, Schönborn-Kellenberger O, Arndt M, Haefeli WE, Krauss J.
Blank A, et al. Among authors: stoll f.
Clin Transl Sci. 2022 Oct;15(10):2366-2377. doi: 10.1111/cts.13365. Epub 2022 Jul 23.
Clin Transl Sci. 2022.
PMID: 35869929
Free PMC article.
Clinical Trial.